A recent study found that a drug called zanamifene can lower blood pressure by as much as 2mmHg when used in combination with a blood pressure medication like norepinephrine.
But the drug is not yet available in the U.S. and, in some cases, the drug can be expensive.
A study published in JAMA Internal Medicine on Tuesday found that patients taking zanemifene had a 3.3% greater risk of death, while those who took a placebo had a 1.9% greater death risk.
In addition, the study found an increased risk of heart attack among patients taking norepinephrine.
The new study, published in the New England Journal of Medicine, was the first to find that the drug, which was developed by Pfizer and AstraZeneca, lowers blood pressure significantly when given with a medication called norepinphrine.
The drug has been on the market since 2007.
The authors also found that zanafenac, which is manufactured by a different company, was more effective at lowering blood pressure than norephenphrine.
In other words, the researchers found that norepenphrine is not as effective at keeping blood pressure down as zanaceten.
The new study found a similar pattern of results.
“We found that the effects of zanapenac were not significantly different than the effects observed with zanabenac,” lead researcher Andrew S. Riggs, MD, told CNN.
In a press release, Pfizer noted that the results are important because the drug has not yet been approved by the Food and Drug Administration.
“This research is an important step forward in understanding the mechanisms by which norephrine and zanpens slow the development of cardiovascular disease,” Dr. Riggles said.
“Norepines and zanosens may reduce the risk of cardiovascular events by increasing blood flow to tissues, which may reduce inflammation and improve blood clotting.”
It is also important to note that while this study found significant reduction in the risk for death from heart attacks, it was not clear whether this was due to increased levels of nitric oxide or vascular calcification,” the release continued.
Zanapens and norepasens have been on clinical trials for several years, but the drug companies have not announced their approval dates.
It is unclear whether the drugs are currently available for use in the United States, but they do have a limited supply.
If they are approved, the drugs would likely be prescribed in combination.
The FDA has not responded to CNN’s requests for comment.